Unibest

Pharmaceutical intermediates

Erlotinib Intermediates

2 pharmaceutical intermediates for Erlotinib. Indication: Pancreatic Neoplasm; Carcinoma, Non-Small-Cell Lung.

提交项目All intermediates

About Erlotinib

Originator
Genentech
Indication
Pancreatic Neoplasm; Carcinoma, Non-Small-Cell Lung
Approved Date
12/18/2004

Available intermediates

2 intermediates currently listed for Erlotinib. Request specifications, documentation or a quotation for any item below.

Erlotinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
Ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate hydrochloride183322-17-0//
4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline183322-18-1//

Other programs under E

Edoxaban tosylate monohydrateElacestrantElagolix SodiumEldecalcitolElinzanetantElobixibatEltrombopagEltrombopag Olamine

Building toward Erlotinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →